ACADIA Pharmaceuticals, Inc. (ACAD) Investigated by Block & Leviton LLP For Violations of Federal Securities Laws

BOSTON, July 18, 2018 /PRNewswire/ -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, is investigating whether ACADIA Pharmaceuticals, Inc. ("ACADIA" or the "Company") (NASDAQ: ACAD) and certain of its officers and directors violated federal securities laws.

On April 9, 2018, CNN reported that ACADIA's Nuplazid treatment may have played a role in the death of ill and elderly patients. On this news, shares in the Company plunged 23%. Subsequently, on July 9, 2018, the Southern Investigative Reporting Foundation released a report alleging that the Company's approach to government approval is best described as "loophole-centric." Following this report, the Company's shares dropped more than 6%.

If you purchased or otherwise acquired ACADIA securities and have questions about your legal rights, or possess information relevant to this investigation, you are encouraged to contact attorney John DeFelice at (888) 868-2385, by email at john@blockesq.com or by visiting http://shareholder.law/acadia.

Block & Leviton LLP was recently ranked 4th among securities litigation firms by ISS for recoveries in 2017. The firm represents many of the nations' largest institutional investors and numerous individual investors in securities litigation throughout the country. Indeed, its lawyers have recovered billions of dollars for its clients.

This notice may constitute attorney advertising.

CONTACT:

BLOCK & LEVITON LLP
John DeFelice
(617) 398-5600 phone
155 Federal Street, Suite 400
Boston, MA 02110
john@blockesq.com

View original content:http://www.prnewswire.com/news-releases/acadia-pharmaceuticals-inc-acad-investigated-by-block--leviton-llp-for-violations-of-federal-securities-laws-300683034.html

SOURCE Block & Leviton LLP